Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.
Castaño-Díez S, López-Guerra M, Zugasti I, Calvo X, Schulz FI, Avendaño A, Mora E, Falantes J, Azaceta G, Ibáñez M, Chen T, Notario C, Amer N, Palomo L, Pomares H, Vila J, Bernal Del Castillo T, Jiménez-Vicente C, Esteban D, Guijarro F, Álamo J, Cortés-Bullich A, Torrecillas-Mayayo V, Triguero A, Mont-de Torres L, Carcelero E, Cardús A, Germing U, Betz B, Rozman M, Arenillas L, Zamora L, Díez-Campelo M, Xicoy B, Esteve J, Díaz-Beyá M. Castaño-Díez S, et al. Among authors: jimenez vicente c. Blood Adv. 2025 Jan 14;9(1):39-53. doi: 10.1182/bloodadvances.2024013648. Blood Adv. 2025. PMID: 39388660
Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?
Castaño-Díez S, Álamo JR, López-Guerra M, Gómez-Hernando M, Zugasti I, Jiménez-Vicente C, Guijarro F, López-Oreja I, Esteban D, Charry P, Torrecillas V, Mont-de Torres L, Cortés-Bullich A, Bataller Á, Guardia A, Munárriz D, Carcelero E, Riu G, Triguero A, Tovar N, Vela D, Beà S, Costa D, Colomer D, Rozman M, Esteve J, Díaz-Beyá M. Castaño-Díez S, et al. Among authors: jimenez vicente c. Oncologist. 2024 Sep 30:oyae246. doi: 10.1093/oncolo/oyae246. Online ahead of print. Oncologist. 2024. PMID: 39349391 Free article.
Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study.
Jiménez-Vicente C, Guardia-Torrelles A, Pérez-Valencia AI, Martínez-Roca A, Castaño-Diez S, Guijarro F, Cortés-Bullich A, Merchán B, Triguero A, Hernández I, Brillembourg H, Munárriz D, Zugasti I, Fernández-Avilés F, Diaz-Beyá M, Esteve J. Jiménez-Vicente C, et al. Ann Hematol. 2024 Oct;103(10):4033-4043. doi: 10.1007/s00277-024-05923-5. Epub 2024 Aug 29. Ann Hematol. 2024. PMID: 39207559 Free PMC article.
Whole Exome Sequencing of Intermediate-Risk Acute Myeloid Leukemia without Recurrent Genetic Abnormalities Offers Deeper Insights into New Diagnostic Classifications.
Guijarro F, Castaño-Díez S, Jiménez-Vicente C, Garrote M, Álamo JR, Gómez-Hernando M, López-Oreja I, Morata J, López-Guerra M, López C, Beà S, Costa D, Colomer D, Díaz-Beyá M, Rozman M, Esteve J. Guijarro F, et al. Among authors: jimenez vicente c. Int J Mol Sci. 2024 Aug 8;25(16):8669. doi: 10.3390/ijms25168669. Int J Mol Sci. 2024. PMID: 39201354 Free PMC article.
Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.
Jiménez-Vicente C, Charry P, Castaño-Diez S, Guijarro F, López-Guerra M, Pérez-Valencia AI, Martinez-Roca A, Cortés-Bullich A, Munárriz D, Solano MT, Rosiñol L, Carreras E, Urbano-Ispizua Á, Fernández-Avilés F, Martinez C, Suárez-Lledó M, Díaz-Beyá M, Rovira M, Salas MQ, Esteve J. Jiménez-Vicente C, et al. Br J Haematol. 2024 Jul;205(1):256-267. doi: 10.1111/bjh.19518. Epub 2024 May 29. Br J Haematol. 2024. PMID: 38811025
Allogeneic hematopoietic cell transplantation with sequential conditioning regimen in relapsed refractory acute myeloid leukemia.
Tolosa-Ridao C, Suárez-Lledó M, Jiménez-Vicente C, Cortés-Bullich A, Merchan B, Martínez-Roca A, Guijarro F, Castaño-Díez S, Rosiñol L, Fernández-Avilés F, Martínez C, Díaz-Beya M, Esteve J, Rovira M, Salas MQ. Tolosa-Ridao C, et al. Among authors: jimenez vicente c. Bone Marrow Transplant. 2024 Aug;59(8):1199-1201. doi: 10.1038/s41409-024-02310-6. Epub 2024 May 22. Bone Marrow Transplant. 2024. PMID: 38778147 No abstract available.
A novel ETV6::FGFR1 fusion gene in a myeloid/lymphoid neoplasm with FGFR1 rearrangement sensitive to specific FGFR1-2-3 inhibition.
Jiménez-Vicente C, Garrote M, López-Guerra M, Villamón E, Guijarro F, Perez-Valencia AI, Martinez-Roca A, Balaguer O, Álvarez-Larrán A, Hernández-Boluda JC, Rovira M, Colomer D, Diaz-Beyá M, Rozman M, Esteve J. Jiménez-Vicente C, et al. Leuk Lymphoma. 2024 Mar;65(3):394-398. doi: 10.1080/10428194.2023.2295788. Epub 2023 Dec 20. Leuk Lymphoma. 2024. PMID: 38117930 No abstract available.
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.
Jimenez-Chillon C, Othman J, Taussig D, Jimenez-Vicente C, Martinez-Roca A, Tiong IS, Jain M, Aries J, Cakmak S, Knapper S, Kristensen DT, Murthy V, Galani JZ, Kallmeyer C, Ngu L, Veale D, Bolam S, Orfali N, Parker A, Manson C, Parker J, Erblich T, Richardson D, Mokretar K, Potter N, Overgaard UM, Roug AS, Wei AH, Esteve J, Jädersten M, Russell N, Dillon R. Jimenez-Chillon C, et al. Among authors: jimenez vicente c. Blood Adv. 2024 Jan 23;8(2):343-352. doi: 10.1182/bloodadvances.2023011106. Blood Adv. 2024. PMID: 38039513 Free PMC article.
Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.
Castaño-Díez S, Pomares H, Esteban D, Guijarro F, Jiménez-Vicente C, Zugasti I, Álamo JR, Mayayo VT, López-Guerra M, de la Fuente C, Charry P, Cortés-Bullich A, Bataller Á, Maluquer C, Colomer D, Rozman M, Arnan M, Xicoy B, Esteve J, Díaz-Beyá M. Castaño-Díez S, et al. Among authors: jimenez vicente c. Br J Haematol. 2024 Mar;204(3):892-897. doi: 10.1111/bjh.19217. Epub 2023 Nov 27. Br J Haematol. 2024. PMID: 38013238
Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF.
Jiménez-Vicente C, Martínez-Roca A, Pomares H, Castaño-Diez S, Guijarro F, López-Guerra M, Bataller A, Esteban D, Cortés-Bullich A, Pérez-Valencia AI, Guardia-Torrelles A, Zugasti I, Rovira M, Fernández-Avilés F, Colomer D, Arnan M, Díaz-Beyá M, Esteve J. Jiménez-Vicente C, et al. Leuk Res. 2023 Dec;135:107403. doi: 10.1016/j.leukres.2023.107403. Epub 2023 Sep 30. Leuk Res. 2023. PMID: 37837718 No abstract available.
14 results